Amicus Therapeutics received approval from the U.S. FDA for Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) 65mg capsules. This two-component therapy is indicated for adults with late-onset Pompe disease (LOPD) who are not improving on their current enzyme replacement therapy (ERT).   Late-onset Pompe disease is a rare, debilitating, and life-threatening lysosomal disorder caused by a deficiency of the enzyme acid alpha-glucosidase (GAA). Reduced levels of GAA lead to the accumulat...